

## Accepted Manuscript


Endothelial cell calpain as a critical modulator of angiogenesis

Yixuan Zhang, Norika Mengchia Liu, Yongchen Wang, Jiyoun Youn,  
Hua Cai

PII: S0925-4439(17)30108-4  
DOI: doi: [10.1016/j.bbadis.2017.03.021](https://doi.org/10.1016/j.bbadis.2017.03.021)  
Reference: BBADIS 64727

To appear in: *BBA - Molecular Basis of Disease*

Received date: 27 November 2016  
Revised date: 4 March 2017  
Accepted date: 28 March 2017



Please cite this article as: Yixuan Zhang, Norika Mengchia Liu, Yongchen Wang, Jiyoun Youn, Hua Cai, Endothelial cell calpain as a critical modulator of angiogenesis, *BBA - Molecular Basis of Disease* (2017), doi: [10.1016/j.bbadis.2017.03.021](https://doi.org/10.1016/j.bbadis.2017.03.021)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Endothelial Cell Calpain As A Critical Modulator of Angiogenesis

Yixuan Zhang Ph.D., Norika Mengchia Liu M.S., Yongchen Wang, M.S., Jiyoun Youn  
Ph.D., Hua Cai MD., Ph.D.\*

Divisions of Molecular Medicine and Cardiology, Departments of Anesthesiology and Medicine,  
Cardiovascular Research Laboratories, David Geffen School of Medicine at University of  
California Los Angeles (UCLA), California, 90095

\*To whom correspondence should be addressed: Dr. Hua Linda Cai, Divisions of Molecular  
Medicine and Cardiology, Departments of Anesthesiology and Medicine, Cardiovascular  
Research Laboratories, David Geffen School of Medicine at University of California Los Angeles,  
650 Charles E. Young Drive, Los Angeles, CA 90095, USA, Tel.: (310)267-2303; Fax: (310)825-  
0132; E-mail: hcai@mednet.ucla.edu

Word Count Total (incl. cover page & references): 8,624

Word Count Abstract: 213

Total number of Figures: 3

Total number of Tables: 1

**Abstract**

Calpains are a family of calcium-dependent non-lysosomal cysteine proteases. In particular, calpains residing in the endothelial cells play important roles in angiogenesis. It has been shown that calpain activity can be increased in endothelial cells by growth factors, primarily vascular endothelial growth factor (VEGF). VEGF/VEGFR2 induces calpain 2 dependent activation of PI3K/AMPK/Akt/eNOS pathway, and consequent nitric oxide production and physiological angiogenesis. Under pathological conditions such as tumor angiogenesis, endothelial calpains can be activated by hypoxia. This review focuses on the molecular regulatory mechanisms of calpain activation, and the newly identified mechanistic roles and downstream signaling events of calpains in physiological angiogenesis, and in the conditions of pathological tumor angiogenesis and diabetic wound healing, as well as retinopathy and atherosclerosis that is also associated with an increase in calpain activity. Furtherly discussed include the differential strategies of modulating angiogenesis through manipulating calpain expression/activity in different pathological settings. Targeted limitation of angiogenesis in cancer and targeted promotion of angiogenesis in diabetic wound healing via modulations of calpains and calpain-dependent signaling mechanisms are of significant translational potential. Emerging strategies of tissue-specific targeting, environment-dependent targeting, and genome-targeted editing may turn out to be effective regimens for targeted manipulation of angiogenesis through calpain pathways, for differential treatments including both attenuation of tumor angiogenesis and potentiation of diabetic angiogenesis.

Keywords: Angiogenesis, Calpain, endothelial cells, VEGF, eNOS, tumor angiogenesis, diabetic wound healing, atherosclerosis, retinopathy, shear stress

## 1 Introduction of calpains

Calpains belong to a family of calcium-dependent cysteine proteases. Calpains proteolytically process substrates to transform their structures to modulate activities. Calpains have been present during evolution. Isoforms of calpains exist in various organisms, ranging from fish to human<sup>1-3</sup>. To date, 15 isoforms have been identified in humans<sup>4</sup>. Calpain 3 is found in skeletal muscle, while calpain 6 in placenta and embryonic muscles, calpain 8 and calpain 9 in gastrointestinal tract, calpain 11 in testis and calpain 12 in hair follicles. Other calpain isoforms are ubiquitously expressed. Among all of the calpain isoforms, calpain 1 and calpain 2 have been widely studied. Of note, calpain 1 and calpain 2 are the only known calpain isoforms expressed in the endothelial cells<sup>5</sup>. Calpain 1 ( $\mu$ -calpain) and calpain 2 (m-calpain) were originally named by  $\mu$ mol or mmol of calcium concentration that is required for their activation in vitro. The requirements for half maximal activities are at approximately 3-50  $\mu$ M and 400-800  $\mu$ M for calpain 1 and calpain 2 respectively<sup>6, 7</sup>. However, additional evidences indicate that both calpains could be activated at physiological calcium concentrations in vivo at 0.4-0.5  $\mu$ M (calpain 1) and 10  $\mu$ M (calpain 2) respectively, although the activation mechanisms may involve specific cellular components, such as membrane ezrin and phosphoinositides<sup>8-14</sup>.

The calpain proteolytic system includes large subunits, small subunit and the endogenous calpain inhibitor calpastatin. Calpain 1 (CAPN1) and calpain 2 (CAPN2) are heterodimeric proteins, consisting of a large 78-80 kDa catalytic subunit and a common 29 kDa small regulatory subunit (CAPN4). Calpastatin has been shown to inhibit both calpain 1 and calpain 2. Upon activation, calpains cleave a broad spectrum of substrates that are involved in several fundamental cellular processes, including cell proliferation, cell migration and cytoskeletal remodeling. Several groups have shown that calpains are required for cell proliferation. Inhibition of calpains leads to reduced proliferation in different cell types, such as pulmonary artery smooth muscle cells, HeLa and WI-38 human fibroblasts<sup>15-17</sup>. It is also reported that calpain-mediated substrate proteolysis is indispensable for cell migration and cytoskeletal remodeling<sup>18, 19</sup>. Attenuated cell migration was observed in cells treated with calpain inhibitors<sup>20, 21</sup>. Calpain-mediated proteolysis of focal adhesion proteins, such as paxillin, focal adhesion kinase and talin, mediates focal adhesion turnover during migration<sup>22-24</sup>. Mouse embryonic fibroblasts obtained from CAPN4 knockout mice displayed repressed migration and impaired organization of cytoskeleton<sup>25</sup>. In this review, we will discuss the mechanistic roles and downstream signaling events of endothelial calpains in both physiological and pathological angiogenesis.

## 2 The structure of calpains

The catalytic large subunit of calpains comprises four domains of I-IV, while the small subunit has two domains V-VI. The N-terminus of domain I undergoes autolysis upon exposure to  $\text{Ca}^{2+}$ <sup>26, 27</sup>. Domain II contains the catalytic sequence of Cys-His-Asn. The crystallographic structure of calpain reveals that in the absence of calcium the active site is disrupted by the separation of the two subdomains, domains IIa and IIb<sup>8, 28</sup>. Upon  $\text{Ca}^{2+}$  binding, however, IIb and IIa form a functional catalytic center following a subtle conformational change<sup>8, 28</sup>. The crystal structure of calpain 2 similarly reveals that during the conformational change, some residues in IIb come into close contact with the membrane<sup>8</sup>. Domain III can bind to phospholipid in  $\text{Ca}^{2+}$ -dependent manner, and may play an important role in  $\text{Ca}^{2+}$ -dependent membrane translocation of calpains<sup>29, 30</sup>. We have recently shown that Ezrin is required for the membrane specific activation of calpain<sup>14</sup>. Domain IV and domain VI each contains five EF-hand motifs. It has been shown that the first to third EF-hands bind  $\text{Ca}^{2+}$  and the fifth EF-hand motif is involved in heterodimer formation of the large subunit and the small subunit. Domain IV and domain VI are also involved in binding to calpastatin<sup>31</sup>. Domain V of the regulatory small subunit contains hydrophobic Gly-rich sequence<sup>32, 33</sup>. Deletion of domain V reduced membrane binding and localization<sup>34</sup>. Most of this domain is cut off by autolysis, indicating no involvement in protease activity.

## 3 Activation of calpains in endothelial cells

Activation of calpains in endothelial cells is induced by growth factors, primarily vascular endothelial growth factor (VEGF). It has been reported that VEGF activates calpains in endothelial cells, which can be attenuated by calpain inhibitors calpeptin, ALLN and calpastatin<sup>14, 35, 36</sup>. The detailed mechanisms of calpain activation by VEGF are discussed below. The combination of VEGF and basic fibroblast growth factor (FGF) was reported to significantly elevate calpain activity in endothelial cells, as well as the cleavage of calpain substrate vimentin<sup>37</sup>. Another growth factor that has been shown to activate calpain 2 in endothelial cells is epidermal growth factor (EGF). It has been recently reported that EGF induces calpain 2 membrane translocation and activation in endothelial cells through phosphatidylinositol 4,5-

bisphosphate<sup>38</sup>. Nonetheless, VEGF seems to be the primarily characterized activator of calpain signaling in endothelial cells.

Under physiological conditions, activation of calpain by VEGF results in endothelial nitric oxide synthase (eNOS) phosphorylation to produce nitric oxide (NO<sup>•</sup>), which is a potent angiogenic activator<sup>14</sup>. It is known that VEGF activates eNOS/NO<sup>•</sup> through PI3K/Akt<sup>39-41</sup>. Our group recently identified a novel role of calpain 2 in mediating VEGF-induced PI3K/AMPK/Akt activation, and subsequent eNOS phosphorylation and NO<sup>•</sup> production in endothelial cells<sup>14</sup>. Application of calpain inhibitors (ALLN or Calpeptin), or siRNA targeting calpain 2, abolished VEGF-induced activation of PI3K/AMPK/Akt/eNOS/NO<sup>•</sup> pathway. However, calpain 1 is not involved in this response<sup>14</sup>. Taken together, these data indicate a unique role of calpain 2 in mediating VEGF-induced angiogenesis. Other reports also support the specific role of calpain 2 in mediating VEGF downstream signaling<sup>42</sup>. It has been shown that VEGF selectively activates calpain 2 in endothelial cells<sup>42</sup>. The activation of calpain 2 by VEGF may be caused by preferably increased calpain 2 protein expression. Su et al. demonstrated that the protein abundance of calpain 2 was increased 2 hrs post VEGF stimulation<sup>43</sup>. However, calpain 1 expression was unchanged, suggesting that elevated calpain activity is attributed to increased calpain 2 protein content<sup>43,44</sup>. Our group has further revealed a calpain dependent negative feedback loop to inhibit VEGFR2 overactivation<sup>45</sup>. Cleavage and activation of protein tyrosine phosphatase type 1 (PTP1B) by calpain de-phosphorylates VEGFR2<sup>45</sup>. Altered expression or activity of PTP1B and/or calpain modulated VEGF-induced angiogenesis and diabetic wound healing in mice<sup>45</sup>. Illustrations on a role of endothelial calpain 2 in VEGF-induced angiogenesis are presented in Fig. 1. Roles of calpain pathways in physiological and pathological angiogenesis are further discussed in the section 4 below.

Moreover, calpains are activated when endothelial cells are exposed to hypoxia<sup>46-49</sup>. Zhang et al. reported that short exposure of endothelial cells to hypoxia (1-12 hr) up-regulated mRNA level and activity of calpain<sup>47</sup>. Treatments of actinomycin D (a transcriptional inhibitor) and ALLN prevented hypoxia-induced calpain 2 transcription and activation, implicating a potential regulation at transcriptional level<sup>47</sup>. Though VEGF is transcriptionally regulated by hypoxia inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ) during hypoxia, the transcription regulation of calpain mRNA may be facilitated directly by hypoxia in short exposure. For longer exposure to hypoxia, calpain activation could be mediated by HIF-1 $\alpha$ -induced VEGF or Na<sup>+</sup>/H<sup>+</sup> exchanger-1 (NHE1) expression<sup>49</sup>. Similar to VEGF, NHE1 is also a HIF-1 $\alpha$  target. Both mRNA and protein levels of

NHE1 are up-regulated by hypoxia (48 hr) or adenovirus-delivered HIF-1 $\alpha$  (24 hr)<sup>49, 50</sup>. Knockdown of NHE1 selectively inhibited HIF-1 $\alpha$ -induced calpain 2 protein expression and activation, and subsequent angiogenesis<sup>49</sup>. These pathways are included in Fig. 2 for mechanisms of tumor angiogenesis involving calpain activation.

In addition to selective induction of calpain 2 expression, calpain activation is subjected to spatial regulations. We have shown that in response to VEGF stimulation, only the membrane-localized calpain is activated and inhibited by calpain inhibitors (ALLN and calpeptin). Furthermore, we also found that VEGF induces direct binding of calpain and ezrin<sup>14</sup>. Membrane colocalization of these two proteins can be detected within 10 min of VEGF stimulation. The activity of calpain in the membrane fraction was greatly decreased by ezrin siRNA<sup>14</sup>. These results suggest that ezrin mediates calpain membrane translocation and activation as a novel mechanism of regulating calpain in endothelial cells. Another mechanism of calpain membrane activation involves phosphoinositides. Studies from different groups have shown that phosphoinositides, components of the membrane, interact with calpain 1 and 2 through calpain domain III<sup>10, 30, 51</sup>. Sphingosine 1-phosphate (S1P) induces calpain membrane translocation and activation without changing calpain expression level<sup>52</sup>. More evidence of calpain membrane localization was shown by the study of the crystal structure of calpain 2<sup>8</sup>.

Furthermore, calpain activation in endothelial cells involves calpastatin, the endogenous calpain inhibitor. It was reported that calpastatin binds to calpains in response to calcium to prevent calpains from activation<sup>53</sup>. Calpastatin has four inhibitory domains and each one of those is able to bind to one calpain molecule. Each inhibitory domain contains three subdomains, A, B and C. Subdomains A and C bind to calpain domain IV and domain IV, respectively<sup>31, 54</sup>. A recent study has shown that calpastatin binds to the active cleft of calpains by looping out around the active site, so that calpastatin blocks the active site without being cleaved<sup>54</sup>. Treatment of endothelial cells with VEGF potently down-regulated calpastatin expression, leading to increased calpain activity<sup>44</sup>. The combined regulations of calpastatin and calpain enable maximal activation of calpain and its downstream signaling in response to VEGF.

Therefore, calpain 2 activation in endothelial cells can be induced through at least three different mechanisms: 1) selective up-regulation of calpain 2 protein abundance and activity<sup>14, 43, 55</sup>; 2) spatial regulation of calpain subcellular localization to promote membrane translocation and activation<sup>14, 56</sup>; and 3) down-regulation of calpain inhibitor calpastatin<sup>44</sup>. The mechanistic

pathways of calpain 2 activation by VEGF to mediate angiogenesis are summarized in Fig. 1. Calpain 2 inhibition suppresses multiple features of angiogenesis, such as proliferation<sup>56, 57</sup>, cell migration<sup>42, 55, 58</sup> and tube formation<sup>42, 43, 55, 58</sup>.

## **4 Role of calpains in angiogenesis**

### **4.1 General introduction of angiogenesis**

Angiogenesis is the process of new vessel formation from existing vessels. Angiogenesis requires a highly coordinated series of events that involve the interactions among endothelial cells, extra-cellular matrix and growth factors. Key steps of angiogenesis include endothelial cell proliferation, migration and tube formation (the formation of capillary-like tube structures). Basic physiology of angiogenesis has been discussed in several recent reviews<sup>59-61</sup>. VEGF is one of the main initiators of angiogenesis. We and others have shown that VEGF exposure induces calpain 2 dependent activation of PI3K/AMPK/Akt/eNOS pathway and NO<sup>•</sup> production in endothelial cells through VEGFR2<sup>14, 45</sup>. Blocking PI3K/AMPK/Akt by pharmacological kinase inhibitors, or genetic/pharmacological abrogation of calpain 2 activation, completely attenuated VEGF-induced NO<sup>•</sup> production and angiogenesis<sup>14, 62-64</sup>. Additionally, angiogenesis is promoted in conditions where ERK is activated. Studies have shown that ERK is activated in response to VEGF/VEGFR2<sup>65</sup>. Abrogated ERK signaling inhibits VEGF-induced angiogenic response of endothelial cells<sup>66</sup>.

### **4.2 Role of calpains in angiogenesis under physiological conditions**

Under physiological conditions, angiogenesis mostly occurs during embryonic development, when it requires adequate vasculature for organ development. Normal angiogenesis in the adulthood usually happens during repair processes, such as wound healing. It has been reported that deletion of the small subunit (CAPN4) of calpain results in elimination of both calpain 1 and calpain 2 activities and embryonic death at day E11.5, implicating a role of calpain in embryonic development<sup>67</sup>. Arthur et al. reported that CAPN4 knockout embryos had reduced yolk sac vasculature at E10.5. The endothelial cells lining the atria were found rounding up at E10.5, and eventually delaminated at E11.5, indicating the indispensable role of calpains in normal vascular development<sup>67</sup>. Using global and conditional knockout strategies, Takano and colleagues have shown that calpain 2 deficiencies caused embryonic death on day 15, due to placental dysfunction-induced apoptosis<sup>68</sup>. Interestingly, calpain 1 knockout alone appeared mostly harmless (viable and fertile)<sup>69</sup>. Double knockout of calpain 1 and calpain 2 potentiated

embryonic lethality (~3 days earlier) however, suggesting that the two isoforms may additively modulate some common developmental pathways *in vivo*, at least during the developmental stage<sup>68</sup>.

Calpains play important roles in wound healing, a physiological process highly dependent on angiogenesis. It has been shown that transgenic mice globally over-expressing calpastatin displayed a striking delay in skin wound healing through impaired angiogenesis, indicating that calpain activity is required for wound healing<sup>70</sup>. We have recently demonstrated that application of calpain inhibitor ALLN to wound bed significantly delayed VEGF-induced wound healing in diabetic mice<sup>45</sup>. However, wound healing is not a process that only involves enhanced angiogenesis. In the late stage of wound healing, a mechanism of vessel dissociation/regression is activated. Interestingly, vessel regression is mediated by calpain 1. Bodnar and colleagues reported that activation of calpain 1 in endothelial cells leads to vessel regression and reduced angiogenesis during middle and late stage of wound healing<sup>71, 72</sup>. Calpain 1-induced dissociation of newly formed vessels is a mechanism to maintain a regular vascular network near the wounded area by eliminating excessive vessels. Moreover, a separate study reported that cells with calpain 1 siRNA transfection showed stabilized tube formation at late stages (6-24 hr)<sup>58</sup>. Of note, the role of calpain 1 during later stage of angiogenesis is established in experiments of exposing endothelial cells to CXCL10 (IP-10), a known ligand for the resolving stage of the wound, rather than VEGF. A potential role of calpain 1 in VEGF-induced wound healing remains to be investigated.

### **4.3 Role of calpains in angiogenesis under pathological conditions**

#### **4.3.1 Calpains in tumor angiogenesis**

The constant growth of solid tumor requires large quantity of oxygen and nutrients. Therefore, tumor cells have developed the ability to establish their own blood supply by the induction of angiogenesis. By secreting angiogenic factors, tumor cells induce angiogenesis around them to achieve nutrient delivery and removal of metabolic wastes through the newly formed vessels. One of the most important angiogenic factors produced by tumor cells is VEGF. Blockade of VEGF or VEGF receptors dramatically inhibited tumor growth via abrogation of angiogenesis<sup>73</sup>. As discussed in the previous section, VEGF activates calpain 2 in endothelial cells<sup>14, 42, 43, 55</sup>. We and others have demonstrated that inhibition of calpain 2 (with siRNA or calpain inhibitors) abolished VEGF-induced endothelial NO<sup>\*</sup> production and angiogenesis<sup>14, 43, 45, 74</sup>. Moreover, the

fast growth of tumor cell results in hypoxia, exposure to which upregulates calpain expression and activity in endothelial cells<sup>46-49, 75, 76</sup>.

Under hypoxic conditions, calpains are involved in the crosstalk between tumor cells and endothelial cells. VEGF is secreted by tumor cells to influence endothelial cells. Interestingly, calpain in tumor cells serves as a newly identified regulator of the HIF-1 $\alpha$ /VEGF pathway<sup>77</sup>. Zheng et al. have shown that hypoxia induces filamin A proteolysis by calpain in melanoma cells, which in turn facilitates HIF-1 $\alpha$  nuclear translocation. Calpeptin inhibition of calpain however attenuated HIF-1 $\alpha$  nuclear accumulation and transactivation<sup>77</sup>. It is known that VEGF is transcriptionally upregulated by HIF-1 $\alpha$ . Over-expression of filamin A increased recruitment of HIF-1 $\alpha$  to VEGF promoter and augmented angiogenesis in a tumor xenograft model<sup>77</sup>. Another crosstalk involves vasohibin-1 (VASH1), an angiogenesis inhibitor generated by VEGF-stimulated endothelial cells<sup>78, 79</sup>. It was reported that hypoxia inhibits VEGF-induced VASH1 expression<sup>79</sup>. Interestingly, tumor cells inactivate VASH1 through calpain-dependent cleavage of VASH1 in EC-tumor cell co-culture experiments<sup>78</sup>. These calpain central tumor cell-EC crosstalks to facilitate angiogenesis are summarized in Fig. 2.

To study the involvement of endothelial calpains in tumor angiogenesis, Miyazaki et al. collected tumors and nearby normal tissues from patients with malignant astrocytoma, colon and lung adenocarcinomas. Immunostaining of calpastatin illustrated that the expression level of calpastatin was significantly reduced in endothelial cells of tumor vessels compared to nearby normal vessels<sup>44</sup>. They further generated transgenic mice that harbor endothelial cell specific transgene of calpastatin. In these animals, tumor angiogenesis was attenuated in a Lewis lung carcinoma allograft transplantation model. It turns out that calpastatin inhibits VEGF-C production through calpain/SOCS3/STAT3<sup>44</sup>. These results provide more evidences that regulation of calpain pathway is important in tumor angiogenesis (summarized in Fig. 2).

#### **4.3.2 Calpains in diabetic wound healing**

Diabetic foot ulcer, one of the most common complications of diabetes mellitus, affects 15% of people with diabetes<sup>80</sup>. It is also the leading cause of amputations among diabetic patients<sup>81, 82</sup>. One of the major causes of diabetic foot ulcer is impaired wound healing, which is characterized by impaired growth factor production and angiogenesis<sup>82-85</sup>. It is known that the expression of growth factors and their receptors (such as VEGF, platelet-derived growth factor (PDGF)/PDGF receptor, FGF/FGF receptor, EGF) is up-regulated in the wounded area under physiological repair<sup>83</sup>. However, the up-regulation of growth factors and their receptors is absent in diabetic

wounds. The synthesis of PDGF and FGF like growth factors was down-regulated in STZ-induced diabetic wound<sup>83, 86</sup>. The abundance of VEGF was decreased in wounded area throughout wound healing process in the db/db mice<sup>87</sup>. Galkowska et. al. have compared the expression of growth factors and their receptors in the margin skin tissue of diabetic foot ulcers with normal non-diabetic foot skin by immunohistochemistry<sup>84</sup>. They reported down-regulation of PDGF receptor and TGF- $\beta$ 1. There was a similar trend for VEGF/VEGFR2, EGF and FGF<sup>84</sup>. In accordance with the impaired production of growth factors, angiogenesis process is also delayed in diabetic wound<sup>88-90</sup>. To promote wound healing through angiogenesis, multiple strategies have been tested. Administration of growth factors has been shown to be effective<sup>45, 91</sup>. Others and we have shown that VEGF activates PI3K/AMPK/Akt/eNOS cascade to induce NO<sup>\*</sup> production, which in turn mediates angiogenesis and wound healing<sup>14, 92, 93</sup>. Topical application of VEGF accelerated skin wound healing in both type 1 and type 2 diabetic models<sup>45, 80</sup>. This strategy and other approaches discussed below to improve diabetic wound healing are summarized in Fig. 3.

To further accelerate wound healing, an alternative approach is to facilitate angiogenesis by targeting downstream pathways of growth factors. We have recently shown that VEGF signaling is regulated by a calpain/PTP1B/VEGFR2 feedback mechanism, which can be employed to enhance VEGF signaling to facilitate therapeutic angiogenesis<sup>45</sup>. PTP1B activity is up-regulated in diabetic wound to constrain VEGFR2, while application of PTP1B inhibitor accelerated VEGF-dependent diabetic wound healing<sup>45</sup>. To test the effect of calpain in wound healing, we directly applied plasmids that encode human calpain cDNA to the wound bed. As expected, we found that calpain over-expression in wound bed accelerated VEGF-induced wound healing in STZ-induced diabetic mice<sup>45</sup>. Data from calpastatin transgenic mice confirmed the importance of calpain in angiogenesis and wound healing. Global calpastatin transgenic mice showed impaired angiogenesis and a striking delay in wound healing<sup>70</sup>. Moreover, calpain 2 is indispensable to lymphangiogenesis<sup>58</sup>, enhancement of which contributed to accelerated diabetic wound healing<sup>80, 94, 95</sup>.

Studies examining roles and mechanisms of calpains in pathophysiological angiogenesis, including models and approaches employed, are summarized in Table 1.

## **5. Other mechanisms that regulate calpain activity in endothelial cells**

### **5.1 Oxidized LDL, phospholipids and mechanical stress**

In addition to growth factors and hypoxia, calpains can be activated in endothelial cells by oxidized low-density lipoprotein (oxLDL), phospholipids or mechanical stress. OxLDL induces calpain activation in endothelial cells through elevated calcium concentration<sup>96, 97</sup>. In human atherosclerotic plaques, calpain activity was identified in apoptotic cells<sup>98</sup>. In addition, oxLDL-induced endothelial cell apoptosis can be partially blocked by PD151746, a calpain 1 inhibitor<sup>99</sup>. These results suggest that at least calpain 1 activation is involved in ox-LDL-induced endothelial apoptosis, which has long been considered as an important regulator of the initiation and progression of atherosclerotic lesions. On the other hand, calpain 2 has been reported to regulate endothelial adherence junctions (through cleavage of VE-cadherin) and promote atherogenesis. Recently, Miyazaki et. al. have shown that endothelial calpain 2 up-regulation is associated with more severe atherosclerotic lesions in patients<sup>100</sup>. In LDL receptor (LDLR) deficiency mice, high cholesterol fed animals showed elevated expression of endothelial calpain 2. Administration of calpain inhibitors (calpeptin, ALLM) on the other hand significantly limited lesion formation in high cholesterol diet-treated LDLR knockout or Apolipoprotein E deficient mice<sup>100</sup>. Similarly, lysophosphatidylcholine, the major lipid constituent of oxLDL, can activate calpain 2 and induce cleavage of VE-cadherin<sup>100, 101</sup>. Taken together, activation of calpain 1 and calpain 2 by oxLDL contributes to atherogenesis. Though a causal role of angiogenesis in atherosclerosis has not been established, there is strong evidence that the development of plaques is associated with neovascularization within the plaque<sup>102-105</sup>.

It has also been reported that calpain 2 is activated by physiological shear stress through elevated intracellular calcium<sup>106, 107</sup>. Calpeptin impaired shear stress-induced focal adhesion polarization and cell alignment under shear conditions<sup>107</sup>. Shear stress, combined with sphingosine 1-phosphate, induces calpain membrane translocation and MTP-MMP1 activation in endothelial cells<sup>52</sup>. On the other hand, Mayazaki et. al. have demonstrated that calpain 2 antagonizes RhoA overactivation and endothelial barrier dysfunction in response to disturbed flow<sup>108</sup>. Overall calpain 2 activation under different flow patterns seem to exert protective signaling via differential mechanisms.

## **5.2 Ischemic retinopathy**

Calpains have been reported to contribute to hypoxia-derived retina cell death in ischemic retinopathy<sup>109, 110</sup>. Using an oxygen-induced retinopathy (OIR) model, Hoang et al. demonstrated that ischemic hypoxia activates calpain in retinal endothelial cells and disrupts actin cytoskeleton in human retinal microvascular endothelial cells<sup>46</sup>. Moderate inhibition (30-

35%) of calpain activity results in formation of functional neovasculature. Further investigation revealed that calpain inhibitor MDL28170 and calpastatin peptide improved organization and alignment of actin cytoskeleton both in vitro and in vivo<sup>46</sup>. The role of calpains in ischemic retinopathy was also reported by another independent group using the OIR model<sup>44</sup>. Endothelial specific transgene of calpastatin abolished OIR-induced vascular tufts through down-regulation of calpain 1-dependent cleavage of SOCS3, followed by inhibition of STAT3 and VEGF-C expression<sup>44</sup>. These results suggest that targeting calpain system (either by application of calpain inhibitor or overexpression of calpastatin) is beneficial for the normalization of angiogenesis in ischemic retinopathy.

#### **6. Differential strategies targeting endothelial calpain and calpain-dependent pathways for different pathophysiological conditions.**

Calpain 1 and calpain 2 are ubiquitously expressed in human tissues. For therapeutic purposes related to angiogenesis, endothelial targeted strategies of modulating calpain activity may be beneficial. Restrain of calpain activity inhibits tumor growth and atherogenesis, and promotes formation of normal vasculature in ischemic retinopathy. On the other hand, activation of calpain is aimed to treat diabetic wound healing and protect endothelial function under shear stress. Therefore, differential strategies of regulating endothelial calpain/angiogenesis are necessary for therapeutic control of different pathophysiological conditions.

One of the options enabling endothelial cell-targeted delivery involves generating genetically modified vectors. Plasmids or viral vectors-based gene targeting could specifically modulate gene expression in certain type of cells, with the help of tissue-specific promoters/enhancers, and sequences with physiological sensing elements (such as those responsive to hypoxia, shear stress)<sup>111, 112</sup>. Localized intraspinal injection into rats of lentiviral vector encoding calpain 1 resulted in sustained ability of proteolysis (activated NF- $\kappa$ Bp65 after I $\kappa$ B being cleaved by calpain 1) up to 7 weeks after injection<sup>113, 114</sup>. It has been reported that hypoxia response element from the promoters of multiple genes (such as erythropoietin, phosphoglycerate kinase-1, and VEGF) has been used as a hypoxia sensitive enhancer to promote transcription of the delivered gene of interest<sup>111, 115-117</sup>. Very recently, lentiviruses that are pseudotyped with endothelial-specific envelopes recognizing endothelial cell surface marker CD105 have been shown to be efficient and specific in endothelial delivery after systemic injection<sup>118</sup>. Tumor endothelial cells were specifically targeted upon intratumoral injection in mice carrying a vascularized human tumor xenograft<sup>118</sup>. Most recently, the emergence of CRISPR/Cas9 gene

editing system further increases the possibility of in vivo genome editing<sup>119-121</sup>. Yin et al. recently reported that systemic delivery of nanoparticle-conjugated Cas9 mRNA and sgRNA/HDR sequences by AAV provided efficient genome editing and less off-target editing in diseased mice<sup>122</sup>.

Especially, tumor cells are known to have lower pH (6.2-6.9) than normal tissues (7.3-7.4) due to the glycolysis under anaerobic environment<sup>123</sup>. Modified nanoparticles can be used as the vehicle of delivery which is capable of pH-dependent drug release and has been shown to effectively inhibit xenografted tumor growth<sup>124-126</sup>. Another approach to achieve local regulation is to apply treatment in situ. In a diabetic wound healing model, topical administration of recombinant VEGF and calpain plasmids accelerated wound closure<sup>45</sup>. This local application is transient and restrained only to wounded area. This approach is especially applicable to dermal treatment.

In conclusion, calpain 1 and calpain 2 play important roles in VEGF-induced angiogenesis in endothelial cells. Blockade of calpain 2 impairs, while activation of calpain 2 promotes, VEGF-induced angiogenesis. In animal models, inhibition of calpain 1 and calpain 2 by calpastatin transgene specifically expressed in endothelial cells efficiently attenuated tumor angiogenesis and tumor growth<sup>44</sup>. Abrogation of calpain activity reduced progression of atherosclerosis and ischemic retinopathy<sup>46, 100, 127</sup>. On the other hand, activation of calpain pathway accelerated diabetic wound healing, and is dispensable to protect from disturb flow-induced endothelial cell barrier dysfunction<sup>45, 108</sup>. Therefore, disease-specific modulations of calpain, combined with endothelial cell-targeted delivery techniques, may prove to be promising strategies for the treatments of pathophysiological conditions associated with angiogenesis.

#### **Conflict of interest declaration**

None of the authors of this manuscript have a conflict of interest.

**Acknowledgements:** This work was supported by National Institute of Health National Heart, Lung and Blood Institute (NHLBI) Grants HL077440 (HC), HL088975 (HC), HL108701 (HC, DGH), HL119968 (HC), an American Heart Association Established Investigator Award (EIA) 12EIA8990025 (HC) and an AHA Postdoctoral Fellowship Award 14POST20380995 (YXZ).

**LITERATURES CITED**

1. Salmeron C, Garcia de la serrana D, Jimenez-Amilburu V, Fontanillas R, Navarro I, Johnston IA, Gutierrez J and Capilla E. Characterisation and expression of calpain family members in relation to nutritional status, diet composition and flesh texture in gilthead sea bream (*Sparus aurata*). *PLoS one*. 2013;8:e75349.
2. Rawlings ND. Bacterial calpains and the evolution of the calpain (C2) family of peptidases. *Biology direct*. 2015;10:66.
3. Macqueen DJ and Wilcox AH. Characterization of the definitive classical calpain family of vertebrates using phylogenetic, evolutionary and expression analyses. *Open biology*. 2014;4:130219.
4. Sorimachi H and Ono Y. Regulation and physiological roles of the calpain system in muscular disorders. *Cardiovasc Res*. 2012;96:11-22.
5. Fujitani K, Kambayashi J, Sakon M, Ohmi SI, Kawashima S, Yukawa M, Yano Y, Miyoshi H, Ikeda M, Shinoki N and Monden M. Identification of mu-, m-calpains and calpastatin

- and capture of mu-calpain activation in endothelial cells. *Journal of cellular biochemistry*. 1997;66:197-209.
6. Goll DE, Thompson VF, Li H, Wei W and Cong J. The calpain system. *Physiological reviews*. 2003;83:731-801.
  7. Cong J, Goll DE, Peterson AM and Kapprell HP. The role of autolysis in activity of the Ca<sup>2+</sup>-dependent proteinases (mu-calpain and m-calpain). *The Journal of biological chemistry*. 1989;264:10096-103.
  8. Strobl S, Fernandez-Catalan C, Braun M, Huber R, Masumoto H, Nakagawa K, Irie A, Sorimachi H, Bourenkow G, Bartunik H, Suzuki K and Bode W. The crystal structure of calcium-free human m-calpain suggests an electrostatic switch mechanism for activation by calcium. *Proceedings of the National Academy of Sciences of the United States of America*. 2000;97:588-92.
  9. Insete J, Hernando V and Garcia-Dorado D. Contribution of calpains to myocardial ischaemia/reperfusion injury. *Cardiovasc Res*. 2012;96:23-31.
  10. Saido TC, Shibata M, Takenawa T, Murofushi H and Suzuki K. Positive regulation of mu-calpain action by polyphosphoinositides. *The Journal of biological chemistry*. 1992;267:24585-90.
  11. Matsumura Y, Saeki E, Otsu K, Morita T, Takeda H, Kuzuya T, Hori M and Kusuoka H. Intracellular calcium level required for calpain activation in a single myocardial cell. *Journal of molecular and cellular cardiology*. 2001;33:1133-42.
  12. Melloni E, Michetti M, Salamino F and Pontremoli S. Molecular and functional properties of a calpain activator protein specific for mu-isoforms. *The Journal of biological chemistry*. 1998;273:12827-31.
  13. Melloni E, Averna M, Salamino F, Sparatore B, Minafra R and Pontremoli S. Acyl-CoA-binding protein is a potent m-calpain activator. *The Journal of biological chemistry*. 2000;275:82-6.
  14. Youn JY, Wang T and Cai H. An ezrin/calpain/PI3K/AMPK/eNOSs1179 signaling cascade mediating VEGF-dependent endothelial nitric oxide production. *Circulation research*. 2009;104:50-9.
  15. Abeyrathna P, Kovacs L, Han W and Su Y. Calpain-2 activates Akt via TGF-beta1-mTORC2 pathway in pulmonary artery smooth muscle cells. *American journal of physiology Cell physiology*. 2016;311:C24-34.

16. Zhang W, Lane RD and Mellgren RL. The major calpain isozymes are long-lived proteins. Design of an antisense strategy for calpain depletion in cultured cells. *The Journal of biological chemistry*. 1996;271:18825-30.
17. Zhang W, Lu Q, Xie ZJ and Mellgren RL. Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone: evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition. *Oncogene*. 1997;14:255-63.
18. Perrin BJ, Amann KJ and Huttenlocher A. Proteolysis of cortactin by calpain regulates membrane protrusion during cell migration. *Molecular biology of the cell*. 2006;17:239-50.
19. Jeong SY, Martchenko M and Cohen SN. Calpain-dependent cytoskeletal rearrangement exploited for anthrax toxin endocytosis. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110:E4007-15.
20. Saraiva N, Prole DL, Carrara G, Johnson BF, Taylor CW, Parsons M and Smith GL. hGAAP promotes cell adhesion and migration via the stimulation of store-operated Ca<sup>2+</sup> entry and calpain 2. *The Journal of cell biology*. 2013;202:699-713.
21. Svensson L, McDowall A, Giles KM, Stanley P, Feske S and Hogg N. Calpain 2 controls turnover of LFA-1 adhesions on migrating T lymphocytes. *PloS one*. 2010;5:e15090.
22. Cortesio CL, Boateng LR, Piazza TM, Bennin DA and Huttenlocher A. Calpain-mediated proteolysis of paxillin negatively regulates focal adhesion dynamics and cell migration. *The Journal of biological chemistry*. 2011;286:9998-10006.
23. Chan KT, Bennin DA and Huttenlocher A. Regulation of adhesion dynamics by calpain-mediated proteolysis of focal adhesion kinase (FAK). *The Journal of biological chemistry*. 2010;285:11418-26.
24. Franco SJ, Rodgers MA, Perrin BJ, Han J, Bennin DA, Critchley DR and Huttenlocher A. Calpain-mediated proteolysis of talin regulates adhesion dynamics. *Nature cell biology*. 2004;6:977-83.
25. Dourdin N, Bhatt AK, Dutt P, Greer PA, Arthur JS, Elce JS and Huttenlocher A. Reduced cell migration and disruption of the actin cytoskeleton in calpain-deficient embryonic fibroblasts. *The Journal of biological chemistry*. 2001;276:48382-8.
26. Goll DE, Thompson VF, Taylor RG and Zalewska T. Is calpain activity regulated by membranes and autolysis or by calcium and calpastatin? *BioEssays : news and reviews in molecular, cellular and developmental biology*. 1992;14:549-56.
27. Huang Y and Wang KK. The calpain family and human disease. *Trends in molecular medicine*. 2001;7:355-62.

28. Moldoveanu T, Hosfield CM, Lim D, Elce JS, Jia Z and Davies PL. A Ca(2+) switch aligns the active site of calpain. *Cell*. 2002;108:649-60.
29. Carragher NO. Calpain inhibition: a therapeutic strategy targeting multiple disease states. *Current pharmaceutical design*. 2006;12:615-38.
30. Shao H, Chou J, Baty CJ, Burke NA, Watkins SC, Stolz DB and Wells A. Spatial localization of m-calpain to the plasma membrane by phosphoinositide biphosphate binding during epidermal growth factor receptor-mediated activation. *Molecular and cellular biology*. 2006;26:5481-96.
31. Wendt A, Thompson VF and Goll DE. Interaction of calpastatin with calpain: a review. *Biological chemistry*. 2004;385:465-72.
32. Hosfield CM, Elce JS, Davies PL and Jia Z. Crystal structure of calpain reveals the structural basis for Ca(2+)-dependent protease activity and a novel mode of enzyme activation. *The EMBO journal*. 1999;18:6880-9.
33. Jia Z, Hosfield CM, Davies PL and Elce JS. Crystal structure of calpain and insights into Ca(2+)-dependent activation. *Methods in molecular biology*. 2002;172:51-67.
34. Fernandez-Montalvan A, Assfalg-Machleidt I, Pfeiler D, Fritz H, Jochum M and Machleidt W. Mu-calpain binds to lipid bilayers via the exposed hydrophobic surface of its Ca<sup>2+</sup>-activated conformation. *Biological chemistry*. 2006;387:617-27.
35. Maki M, Bagci H, Hamaguchi K, Ueda M, Murachi T and Hatanaka M. Inhibition of calpain by a synthetic oligopeptide corresponding to an exon of the human calpastatin gene. *The Journal of biological chemistry*. 1989;264:18866-9.
36. Hoang MV, Nagy JA, Fox JE and Senger DR. Moderation of calpain activity promotes neovascular integration and lumen formation during VEGF-induced pathological angiogenesis. *PloS one*. 2010;5:e13612.
37. Kwak HI, Kang H, Dave JM, Mendoza EA, Su SC, Maxwell SA and Bayless KJ. Calpain-mediated vimentin cleavage occurs upstream of MT1-MMP membrane translocation to facilitate endothelial sprout initiation. *Angiogenesis*. 2012;15:287-303.
38. Leloup L, Shao HS, Bae YH, Deasy B, Stolz D, Roy P and Wells A. m-calpain Activation Is Regulated by Its Membrane Localization and by Its Binding to Phosphatidylinositol 4,5-Bisphosphate. *Journal of Biological Chemistry*. 2010;285:33549-33566.
39. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R and Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. *Nature*. 1999;399:601-5.

40. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A and Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. *Nature*. 1999;399:597-601.
41. Papapetropoulos A, Garcia-Cardena G, Madri JA and Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. *The Journal of clinical investigation*. 1997;100:3131-9.
42. Bodnar RJ, Yates CC and Wells A. IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. *Circulation research*. 2006;98:617-25.
43. Su Y, Cui Z, Li Z and Block ER. Calpain-2 regulation of VEGF-mediated angiogenesis. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2006;20:1443-51.
44. Miyazaki T, Taketomi Y, Saito Y, Hosono T, Lei XF, Kim-Kaneyama JR, Arata S, Takahashi H, Murakami M and Miyazaki A. Calpastatin counteracts pathological angiogenesis by inhibiting suppressor of cytokine signaling 3 degradation in vascular endothelial cells. *Circulation research*. 2015;116:1170-81.
45. Zhang Y, Li Q, Youn JY and Cai H. Protein Phosphotyrosine Phosphatase 1B (PTP1B) in Calpain-dependent Feedback Regulation of Vascular Endothelial Growth Factor Receptor (VEGFR2) in Endothelial Cells: IMPLICATIONS IN VEGF-DEPENDENT ANGIOGENESIS AND DIABETIC WOUND HEALING. *The Journal of biological chemistry*. 2017;292:407-416.
46. Hoang MV, Smith LE and Senger DR. Calpain inhibitors reduce retinal hypoxia in ischemic retinopathy by improving neovascular architecture and functional perfusion. *Biochimica et biophysica acta*. 2011;1812:549-57.
47. Zhang J, Patel JM and Block ER. Hypoxia-specific upregulation of calpain activity and gene expression in pulmonary artery endothelial cells. *The American journal of physiology*. 1998;275:L461-8.
48. Su Y and Block ER. Acute hypoxia increases intracellular L-arginine content in cultured porcine pulmonary artery endothelial cells. *Journal of cellular physiology*. 1996;167:349-53.
49. Mo XG, Chen QW, Li XS, Zheng MM, Ke DZ, Deng W, Li GQ, Jiang J, Wu ZQ, Wang L, Wang P, Yang Y and Cao GY. Suppression of NHE1 by small interfering RNA inhibits HIF-1 $\alpha$ -induced angiogenesis in vitro via modulation of calpain activity. *Microvascular research*. 2011;81:160-8.
50. Shimoda LA, Fallon M, Pisarcik S, Wang J and Semenza GL. HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial

myocytes. *American journal of physiology Lung cellular and molecular physiology*. 2006;291:L941-9.

51. Tompa P, Emori Y, Sorimachi H, Suzuki K and Friedrich P. Domain III of calpain is a  $Ca^{2+}$ -regulated phospholipid-binding domain. *Biochemical and biophysical research communications*. 2001;280:1333-9.

52. Kang H, Kwak HI, Kaunas R and Bayless KJ. Fluid shear stress and sphingosine 1-phosphate activate calpain to promote membrane type 1 matrix metalloproteinase (MT1-MMP) membrane translocation and endothelial invasion into three-dimensional collagen matrices. *The Journal of biological chemistry*. 2011;286:42017-26.

53. Aversa M, De Tullio R, Capini P, Salamino F, Pontremoli S and Melloni E. Changes in calpastatin localization and expression during calpain activation: a new mechanism for the regulation of intracellular  $Ca^{2+}$ -dependent proteolysis. *Cellular and molecular life sciences : CMLS*. 2003;60:2669-78.

54. Hanna RA, Campbell RL and Davies PL. Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin. *Nature*. 2008;456:409-12.

55. Ma H, Tochigi A, Shearer TR and Azuma M. Calpain inhibitor SNJ-1945 attenuates events prior to angiogenesis in cultured human retinal endothelial cells. *Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics*. 2009;25:409-14.

56. Letavernier B, Zafrani L, Nassar D, Perez J, Levi C, Bellocq A, Mesnard L, Sachon E, Haymann JP, Aractingi S, Faussat AM, Baud L and Letavernier E. Calpains contribute to vascular repair in rapidly progressive form of glomerulonephritis: potential role of their externalization. *Arteriosclerosis, thrombosis, and vascular biology*. 2012;32:335-42.

57. Su Y, Cao W, Han Z and Block ER. Cigarette smoke extract inhibits angiogenesis of pulmonary artery endothelial cells: the role of calpain. *American journal of physiology Lung cellular and molecular physiology*. 2004;287:L794-800.

58. Prangsaengtong O, Senda K, Doki Y, Park JY, Jo M, Sakurai H, Shibahara N, Saiki I and Koizumi K. Calpain 1 and -2 play opposite roles in cord formation of lymphatic endothelial cells via eNOS regulation. *Human cell*. 2012;25:36-44.

59. Adams RH and Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. *Nature reviews Molecular cell biology*. 2007;8:464-78.

60. Otrrock ZK, Mahfouz RA, Makarem JA and Shamseddine AI. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. *Blood cells, molecules & diseases*. 2007;39:212-20.

61. Potente M, Gerhardt H and Carmeliet P. Basic and therapeutic aspects of angiogenesis. *Cell*. 2011;146:873-87.
62. Liu LZ, Jiang Y, Carpenter RL, Jing Y, Peiper SC and Jiang BH. Role and mechanism of arsenic in regulating angiogenesis. *PLoS one*. 2011;6:e20858.
63. Radisavljevic Z, Avraham H and Avraham S. Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/Nitric oxide pathway and modulates migration of brain microvascular endothelial cells. *The Journal of biological chemistry*. 2000;275:20770-4.
64. Matsunaga T, Weihrauch DW, Moniz MC, Tessmer J, Warltier DC and Chilian WM. Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. *Circulation*. 2002;105:2185-91.
65. Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD and Wink DA. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. *Proceedings of the National Academy of Sciences of the United States of America*. 2005;102:13147-52.
66. Zhang Y, Jiang X, Qin X, Ye D, Yi Z, Liu M, Bai O, Liu W, Xie X, Wang Z, Fang J and Chen Y. RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma. *Oncogene*. 2010;29:5404-15.
67. Arthur JS, Elce JS, Hegadorn C, Williams K and Greer PA. Disruption of the murine calpain small subunit gene, *Capn4*: calpain is essential for embryonic development but not for cell growth and division. *Molecular and cellular biology*. 2000;20:4474-81.
68. Takano J, Mihira N, Fujioka R, Hosoki E, Chishti AH and Saido TC. Vital role of the calpain-calpastatin system for placental-integrity-dependent embryonic survival. *Molecular and cellular biology*. 2011;31:4097-106.
69. Azam M, Andrabi SS, Sahr KE, Kamath L, Kuliopulos A and Chishti AH. Disruption of the mouse mu-calpain gene reveals an essential role in platelet function. *Molecular and cellular biology*. 2001;21:2213-20.
70. Nassar D, Letavernier E, Baud L, Aractingi S and Khosrotehrani K. Calpain activity is essential in skin wound healing and contributes to scar formation. *PLoS one*. 2012;7:e37084.
71. Bodnar RJ, Rodgers ME, Chen WC and Wells A. Pericyte regulation of vascular remodeling through the CXC receptor 3. *Arteriosclerosis, thrombosis, and vascular biology*. 2013;33:2818-29.
72. Bodnar RJ, Yates CC, Rodgers ME, Du X and Wells A. IP-10 induces dissociation of newly formed blood vessels. *Journal of cell science*. 2009;122:2064-77.

73. Warren RS, Yuan H, Matli MR, Gillett NA and Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. *The Journal of clinical investigation*. 1995;95:1789-97.
74. Hein TW, Rosa RH, Jr., Ren Y, Xu W and Kuo L. VEGF Receptor-2-Linked PI3K/Calpain/SIRT1 Activation Mediates Retinal Arteriolar Dilations to VEGF and Shear Stress. *Investigative ophthalmology & visual science*. 2015;56:5381-9.
75. Arnould T, Michiels C, Alexandre I and Remacle J. Effect of hypoxia upon intracellular calcium concentration of human endothelial cells. *Journal of cellular physiology*. 1992;152:215-21.
76. Aono Y, Ariyoshi H, Tsuji Y, Ueda A, Tokunaga M, Sakon M and Monden M. Localized activation of m-calpain in human umbilical vein endothelial cells upon hypoxia. *Thrombosis research*. 2001;102:353-61.
77. Zheng X, Zhou AX, Rouhi P, Uramoto H, Boren J, Cao Y, Pereira T, Akyurek LM and Poellinger L. Hypoxia-induced and calpain-dependent cleavage of filamin A regulates the hypoxic response. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111:2560-5.
78. Saito M, Suzuki Y, Yano S, Miyazaki T and Sato Y. Proteolytic inactivation of anti-angiogenic vasohibin-1 by cancer cells. *Journal of biochemistry*. 2016;160:227-232.
79. Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M, Ohta H, Imagawa K, Hojo K, Maki H, Sonoda H and Sato Y. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. *The Journal of clinical investigation*. 2004;114:898-907.
80. Saaristo A, Tammela T, Farkkila A, Karkkainen M, Suominen E, Yla-Herttuala S and Alitalo K. Vascular endothelial growth factor-C accelerates diabetic wound healing. *The American journal of pathology*. 2006;169:1080-7.
81. Brem H, Sheehan P, Rosenberg HJ, Schneider JS and Boulton AJ. Evidence-based protocol for diabetic foot ulcers. *Plastic and reconstructive surgery*. 2006;117:193S-209S; discussion 210S-211S.
82. Brem H and Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. *The Journal of clinical investigation*. 2007;117:1219-22.
83. Shukla A, Dubey MP, Srivastava R and Srivastava BS. Differential expression of proteins during healing of cutaneous wounds in experimental normal and chronic models. *Biochemical and biophysical research communications*. 1998;244:434-9.
84. Galkowska H, Wojewodzka U and Olszewski WL. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers.

*Wound repair and regeneration* : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 2006;14:558-65.

85. Falanga V. Wound healing and its impairment in the diabetic foot. *Lancet*. 2005;366:1736-43.

86. Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal PM, Pesce M, Capogrossi MC, Failla CM, Napolitano M and Odorisio T. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. *The American journal of pathology*. 2006;169:1167-82.

87. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG and Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. *The Journal of biological chemistry*. 1995;270:12607-13.

88. Okizaki S, Ito Y, Hosono K, Oba K, Ohkubo H, Kojo K, Nishizawa N, Shibuya M, Shichiri M and Majima M. Vascular Endothelial Growth Factor Receptor Type 1 Signaling Prevents Delayed Wound Healing in Diabetes by Attenuating the Production of IL-1beta by Recruited Macrophages. *The American journal of pathology*. 2016;186:1481-98.

89. Jing L, Li S and Li Q. Akt/hypoxia-inducible factor-1alpha signaling deficiency compromises skin wound healing in a type 1 diabetes mouse model. *Experimental and therapeutic medicine*. 2015;9:2141-2146.

90. Katagiri S, Park K, Maeda Y, Rao TN, Khamaisi M, Li Q, Yokomizo H, Mima A, Lancerotto L, Wagers A, Orgill DP and King GL. Overexpressing IRS1 in Endothelial Cells Enhances Angioblast Differentiation and Wound Healing in Diabetes and Insulin Resistance. *Diabetes*. 2016;65:2760-71.

91. Wieman TJ, Smiell JM and Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. *Diabetes care*. 1998;21:822-7.

92. Somanath PR, Chen J and Byzova TV. Akt1 is necessary for the vascular maturation and angiogenesis during cutaneous wound healing. *Angiogenesis*. 2008;11:277-88.


93. Lee PC, Salyapongse AN, Bragdon GA, Shears LL, 2nd, Watkins SC, Edington HD and Billiar TR. Impaired wound healing and angiogenesis in eNOS-deficient mice. *The American journal of physiology*. 1999;277:H1600-8.

94. Maruyama K, Asai J, li M, Thorne T, Losordo DW and D'Amore PA. Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. *The American journal of pathology*. 2007;170:1178-91.


95. Cho CH, Sung HK, Kim KT, Cheon HG, Oh GT, Hong HJ, Yoo OJ and Koh GY. COMP-angiopoietin-1 promotes wound healing through enhanced angiogenesis, lymphangiogenesis, and blood flow in a diabetic mouse model (vol 103, pg 4946, 2006). *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103:10146-10146.
96. Sanson M, Ingueneau C, Vindis C, Thiers JC, Glock Y, Rousseau H, Sawa Y, Bando Y, Mallat Z, Salvayre R and Negre-Salvayre A. Oxygen-regulated protein-150 prevents calcium homeostasis deregulation and apoptosis induced by oxidized LDL in vascular cells. *Cell death and differentiation*. 2008;15:1255-65.
97. Vindis C, Elbaz M, Escargueil-Blanc I, Auge N, Henriquez A, Thiers JC, Negre-Salvayre A and Salvayre R. Two distinct calcium-dependent mitochondrial pathways are involved in oxidized LDL-induced apoptosis. *Arteriosclerosis, thrombosis, and vascular biology*. 2005;25:639-45.
98. Goncalves I, Nitulescu M, Saido TC, Dias N, Pedro LM, JF EF, Ares MP and Porn-Ares I. Activation of calpain-1 in human carotid artery atherosclerotic lesions. *BMC cardiovascular disorders*. 2009;9:26.
99. Porn-Ares MI, Saido TC, Andersson T and Ares MP. Oxidized low-density lipoprotein induces calpain-dependent cell death and ubiquitination of caspase 3 in HMEC-1 endothelial cells. *The Biochemical journal*. 2003;374:403-11.
100. Miyazaki T, Taketomi Y, Takimoto M, Lei XF, Arita S, Kim-Kaneyama JR, Arata S, Ohata H, Ota H, Murakami M and Miyazaki A. m-Calpain induction in vascular endothelial cells on human and mouse atheromas and its roles in VE-cadherin disorganization and atherosclerosis. *Circulation*. 2011;124:2522-32.
101. Chaudhuri P, Colles SM, Damron DS and Graham LM. Lysophosphatidylcholine inhibits endothelial cell migration by increasing intracellular calcium and activating calpain. *Arteriosclerosis, thrombosis, and vascular biology*. 2003;23:218-23.
102. Williams JK, Armstrong ML and Heistad DD. Vasa vasorum in atherosclerotic coronary arteries: responses to vasoactive stimuli and regression of atherosclerosis. *Circulation research*. 1988;62:515-23.
103. Zhang Y, Cliff WJ, Schoefl GI and Higgins G. Immunohistochemical study of intimal microvessels in coronary atherosclerosis. *The American journal of pathology*. 1993;143:164-72.
104. Napoli C and Ignarro LJ. Nitric oxide and atherosclerosis. *Nitric oxide : biology and chemistry*. 2001;5:88-97.
105. Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V and Ignarro LJ. Nitric oxide and atherosclerosis: an update. *Nitric oxide : biology and chemistry*. 2006;15:265-79.

106. Ariyoshi H, Yoshikawa N, Aono Y, Tsuji Y, Ueda A, Tokunaga M, Sakon M and Monden M. Localized activation of m-calpain in migrating human umbilical vein endothelial cells stimulated by shear stress. *Journal of cellular biochemistry*. 2001;81:184-92.
107. Miyazaki T, Honda K and Ohata H. Requirement of Ca<sup>2+</sup> influx- and phosphatidylinositol 3-kinase-mediated m-calpain activity for shear stress-induced endothelial cell polarity. *American journal of physiology Cell physiology*. 2007;293:C1216-25.
108. Miyazaki T, Honda K and Ohata H. m-Calpain antagonizes RhoA overactivation and endothelial barrier dysfunction under disturbed shear conditions. *Cardiovasc Res*. 2010;85:530-41.
109. Nakajima E, David LL, Bystrom C, Shearer TR and Azuma M. Calpain-specific proteolysis in primate retina: Contribution of calpains in cell death. *Investigative ophthalmology & visual science*. 2006;47:5469-75.
110. Azuma M and Shearer TR. The role of calcium-activated protease calpain in experimental retinal pathology. *Survey of ophthalmology*. 2008;53:150-63.
111. Modlich U, Pugh CW and Bicknell R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. *Gene therapy*. 2000;7:896-902.
112. Houston P, White BP, Campbell CJ and Braddock M. Delivery and expression of fluid shear stress-inducible promoters to the vessel wall: applications for cardiovascular gene therapy. *Human gene therapy*. 1999;10:3031-44.
113. Lin YC, Brown K and Siebenlist U. Activation of Nf-Kappa-B Requires Proteolysis of the Inhibitor I-Kappa-Alpha - Signal-Induced Phosphorylation of I-Kappa-B-Alpha Alone Does Not Release Active Nf-Kappa-B. *Proceedings of the National Academy of Sciences of the United States of America*. 1995;92:552-556.
114. Yu X, Bondada V, Rogers C, Meyer CA and Yu C. Targeting ERK1/2-calpain 1-NF-κB signal transduction in secondary tissue damage and astrogliosis after spinal cord injury. *Frontiers in Biology*. 2015;10:427-438.
115. Lee M, Rentz J, Bikram M, Han S, Bull DA and Kim SW. Hypoxia-inducible VEGF gene delivery to ischemic myocardium using water-soluble lipopolymer. *Gene therapy*. 2003;10:1535-42.
116. Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S and Naylor S. Hypoxia-mediated tumour targeting. *Gene therapy*. 2003;10:540-9.
117. Pin RH, Reinblatt M and Fong Y. Employing tumor hypoxia to enhance oncolytic viral therapy in breast cancer. *Surgery*. 2004;136:199-204.

118. Abel T, El Filali E, Waern J, Schneider IC, Yuan Q, Munch RC, Hick M, Warnecke G, Madrahimov N, Kontermann RE, Schuttrumpf J, Muller UC, Seppen J, Ott M and Buchholz CJ. Specific gene delivery to liver sinusoidal and artery endothelial cells. *Blood*. 2013;122:2030-8.
119. Haurwitz RE, Jinek M, Wiedenheft B, Zhou K and Doudna JA. Sequence- and structure-specific RNA processing by a CRISPR endonuclease. *Science*. 2010;329:1355-8.
120. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA and Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*. 2012;337:816-21.
121. Cong L, Ran FA, Cox D, Lin SL, Barretto R, Habib N, Hsu PD, Wu XB, Jiang WY, Marraffini LA and Zhang F. Multiplex Genome Engineering Using CRISPR/Cas Systems. *Science*. 2013;339:819-823.
122. Yin H, Song CQ, Dorkin JR, Zhu LJ, Li Y, Wu Q, Park A, Yang J, Suresh S, Bizhanova A, Gupta A, Bolukbasi MF, Walsh S, Bogorad RL, Gao G, Weng Z, Dong Y, Koteliansky V, Wolfe SA, Langer R, Xue W and Anderson DG. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. *Nature biotechnology*. 2016;34:328-33.
123. Cardone RA, Casavola V and Reshkin SJ. The role of disturbed pH dynamics and the Na<sup>+</sup>/H<sup>+</sup> exchanger in metastasis. *Nature reviews Cancer*. 2005;5:786-95.
124. Lee ES, Na K and Bae YH. Polymeric micelle for tumor pH and folate-mediated targeting. *Journal of controlled release : official journal of the Controlled Release Society*. 2003;91:103-13.
125. Lee ES, Na K and Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. *Journal of controlled release : official journal of the Controlled Release Society*. 2005;103:405-18.
126. Sethuraman VA and Bae YH. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. *Journal of controlled release : official journal of the Controlled Release Society*. 2007;118:216-24.
127. Tang F, Chan E, Lu M, Zhang X, Dai C, Mei M, Zhang S, Wang H and Song Q. Calpain-1 Mediated Disorder of Pyrophosphate Metabolism Contributes to Vascular Calcification Induced by oxLDL. *PloS one*. 2015;10:e0129128.




**Fig. 1: VEGF activates angiogenesis through calpain 2.** VEGF/VEGFR2 activates calpain 2, not calpain 1, in endothelial cells. Calpain 2 activation involves binding to Ezzrin and phosphoinositides on the cell membrane. VEGFR2 is negatively regulated by a calpain 2/PTP1B feedback loop. Calpain 2 mediates VEGF-induced activation of PI3K/AMPK/Akt/eNOS pathway and consequent nitric oxide (NO<sup>•</sup>) production and angiogenesis.



**Fig. 2: Calpain central signaling pathways in tumor angiogenesis.** Under hypoxic conditions, von Hippel-Lindau (VHL)-mediated HIF-1 $\alpha$  degradation is inhibited, leading to accumulation of HIF-1 $\alpha$  in both tumor cells and endothelial cells. VEGF expression is transcriptionally upregulated by HIF-1 $\alpha$ . Hypoxia also increases calpain activity in tumor cells. The cleavage of filamin A, a substrate of calpain, facilitates HIF-1 $\alpha$  nuclear translocation and enhances HIF-1 $\alpha$  transactivation, resulting in upregulation of VEGF expression and secretion. On the other hand, hypoxia induces calpain 2 activation in endothelial cells. During acute exposure, hypoxia directly upregulates calpain 2 mRNA, while prolonged exposure to hypoxia increases calpain 2 activity through HIF-1 $\alpha$ -induced VEGF and NHE1 expression. Other growth factors secreted by tumor cells, such as EGF and bFGF, are able to activate endothelial calpain 2 as

well. Down-regulation of calpastatin causes calpain 1-dependent SOCS3 cleavage and VEGF-C production through STAT3 phosphorylation. Activation of endothelial calpain 2 leads to enhanced tumor angiogenesis. Another calpain-dependent upregulation of angiogenesis involves VASH1. Hypoxia inhibits VEGF-induced expression of VASH1 in endothelial cells. Secreted VASH1 undergoes cleavage by tumor calpain, which impairs its anti-angiogenic function.



**Fig. 3: Mechanisms of impaired angiogenesis in diabetic wound healing.** Normal wound healing can be facilitated by VEGF via VEGFR2/calpain 2/eNOS/angiogenesis axis (details see Fig. 1). In diabetes, impaired wound healing is characterized by reduced growth factors expression (VEGF, FGF, and EGF), and increased PTP1B activity to inhibit VEGFR2. To promote angiogenesis in diabetic wound healing, the following strategies can be employed; a) supplementation of VEGF; b) genetic or pharmacological approaches to inhibit PTP1B to increase VEGFR2-dependent angiogenic signaling; or c) genetic or pharmacological approaches to activate calpain.

Table 1: Roles and mechanisms of calpains in pathophysiological angiogenesis

Pathophysiological conditions	In vitro model	In vivo model	Way of intervention	Experimental results	Signaling pathways	References
Wound healing	BAECs. Monolayer wound scratch assay.	STZ-induced diabetic mice. Skin wound healing assay.	In vitro and in vivo: application of calpain inhibitor ALLN.	In vitro and in vivo: delayed VEGF-induced wound closure.	VEGF/calpain/angiogenesis/wound healing	45
			In vivo: overexpression of calpain 1 and calpain 2.	In vivo: accelerated VEGF-induced wound closure.		
Wound healing	N/A	Global calpastatin transgenic mice; Skin wound healing assay.	In vivo: calpastatin transgene.	In vivo: calpastatin Tg mice have impaired cell proliferation, and decreased blood vessel density. Calpastatin Tg mice showed delayed angiogenesis and wound healing.	Calpastatin/calpain/angiogenesis/wound healing	70
Wound healing	Human microvascular cell line (HMEC-1); Tube formation.	N/A	In vitro: IP-10 treatment.  In vitro: application of CI-1 (a pan-calpain inhibitor), CI-IV (calpain 2 inhibitor), BAPTA/AM.	In vitro: leads to $\beta 3$ integrin cleavage and tube dissociation.  In vitro: IP-10-induced tube dissociation was prevented by BAPTA/AM and CI-1, but not CI-IV.  In vitro: IP-10-induced $\beta 3$ integrin cleavage was blocked by BAPTA/AM and CI-1.	IP-10/CXCR3/calpain 1/ $\beta 3$ integrin/tube dissociation (non-VEGF).	72

Tumor angiogenesis	Melanoma cells. Exposure to hypoxia.	Tumor exnograf model for angiogenesis.	In vitro and in vivo: overexpression of filamin A (calpain substrate).  In vitro: application of calpain inhibitor calpeptin.	In vitro: overexpression of filamin A increased HIF-1 $\alpha$ transactivation and VEGF expression (mRNA and secretion) in hypoxia.  In vivo: increased HIF-1 $\alpha$ activity (expected increased VEGF production) and angiogenesis in a tumor xenograft model derived from filamin A overexpression.	Calpain/filamin A/HIF-1 $\alpha$ activity/VEGF/angiogenesis	77
Tumor angiogenesis	Human aortic endothelial cells. Tube formation, cell mobility, proliferation.	Endothelial-specific calpastatin Tg mice.  Lewis lung carcinoma exnograf model.	In vitro: calpastatin siRNA transfection and IL-6 treatment.  In vivo: calpastatin transgene.	In vitro: calpeptin inhibited filamin A cleavage, and HIF-1 $\alpha$ nuclear accumulation and transactivation in melanoma cells (VEGF is transcriptionally regulated by HIF-1 $\alpha$ ).  In vitro: calpastatin siRNA facilitated calpain 1-induced cleavage of SOCS3, leading to VEGF-C production through amplified IL-6-driven STAT3 signals.  Calpastatin siRNA also improved angiogenic responses (tube formation, cell mobility, proliferation) in the presence of IL-6.  In vivo: calpastatin Tg declined phosphorylation of STAT3 in tumors, up-regulated SOCS3 protein expression, and decreased VEGF-C production in the tumor neovessels. Calpastatin Tg suppressed tumor angiogenesis.	Calpastatin/calpain 1/ SOCS3/STAT3 (induced by IL-6)/VEGF- C/angiogenesis	44
Atherosclerosis	HMEC-1	N/A	In vitro: treatments of oxLDL and calpain inhibitor calpeptin.	In vitro: calpeptin inhibited oxLDL-induced calpain activation, Bid cleavage, cytochrom C release, caspase-3 activation, and cytotoxicity.	OxLDL/calcium/calpain/ Bid/cytochrome C/caspase-3/apoptosis	97
Atherosclerosis	HMEC-1	N/A	In vitro: treatments of	In vitro: PD 151746 decreased oxLDL-	OxLDL/calpain/Bid/apo	99

			oxLDL and calpain inhibitor PD 151746. (PD 151746 has more than 20-fold selectivity for calpain 1 over calpain 2.)	induced cytotoxicity. OxLDL-induced Bid cleavage was prevented by PD 151746.	ptosis	
Atherosclerosis	HUVEC	LDLR-KO or apoE-KO mice, fed with high cholesterol food (HCD).	In vitro: transfection of calpain 2 siRNA and treatments of LPC and calpeptin.  In vivo: administration of calpain inhibitors (ALLM and calpeptin).  In vivo transfection of calpain 2 siRNA.	In vitro: LPC-induced VE-cadherin cleavage and hyperpermeability can be blocked by calpeptin or calpain 2 siRNA. LPC-induced dissociation of beta-catenin/VE-cadherin was attenuated by calpeptin. Calpain 2 directly cleaves VE-cadherin.  In vivo: long-term administration of calpain inhibitors attenuated VE-cadherin disorganization and atherosclerotic lesion development.  In vivo: prevented disorganization of VE-cadherin and proatherogenic hyperpermeability in aortic endothelial cells.	HCD or LPC/calpain 2/VE-cadherin/beta-catenin/endothelial adherence junctions/atherosclerosis	100
Ischemic retinopathy	Human dermal microvascular endothelial cells (HDMEC).  Tube formation.	Endothelial-specific calpastatin Tg mice.  Oxygen-induced retinopathy (OIR) model.	In vitro: calpastatin siRNA. IL-6 treatment.  In vivo: endothelial-specific calpastatin transgene.	In vitro: calpastatin siRNA increased IL-6-induced tube formation.  In vivo: calpastatin Tg abolished OIR-induced pathological angiogenesis (vascular tufts formation), upregulated SOCS3 expression and STAT3 phosphorylation, and diminished VEGF-C expression (mRNA).	calpastatin/calpain 1/SOCS3/STAT3/VEGF-C/angiogenesis	44

<p>Ischemic retinopathy</p>	<p>Human retinal microvascular endothelial cells (RMVEC). Capillary-like tube growth in 3D collagen matrix. Exposure to hypoxia.</p>	<p>Oxygen-induced retinopathy model.</p>	<p>In vitro: application of calpain inhibitors: MDL28170, calpastatin.  In vivo: application of MDL28170, PD150606, ALLN.</p>	<p>In vitro: hypoxia induces calpain activation in RMVECs, along with disrupted actin cytoskeleton. Modest inhibition of calpain by MDL28170 or calpastatin improved actin cytoskeletal organization and capillary morphogenesis in a 3D collagen matrix assay.  In vivo: moderate calpain inhibition (by MDL28170, PD150606 or ALLN) improved organization and alignment of actin cytoskeleton and promoted formation of functional neovasculature.</p>	<p>Calpain/cell cytoskeleton (organization and alignment of actin cables)/angiogenesis</p>	<p>46</p>
-----------------------------	--	--	---	--	--	-----------

### Highlights

- Mechanistic roles of endothelial calpain activation in angiogenesis are reviewed.
- Calpain inhibition limits tumor growth and atherogenesis, and improves ischemic retinopathy.
- Calpain activation promotes diabetic wound healing and mediates protective signaling in response to shear stress.
- Strategies differentially targeting calpain pathways may serve as novel therapeutics for different pathophysiological conditions associated with angiogenesis.